Shattuck Labs, Inc. (NASDAQ:STTK) CEO Purchases $49,968.00 in Stock

Shattuck Labs, Inc. (NASDAQ:STTK) CEO Taylor Schreiber bought 14,400 shares of the stock in a transaction on Wednesday, June 26th. The shares were purchased at an average price of $3.47 per share, with a total value of $49,968.00. Following the acquisition, the chief executive officer now owns 34,502 shares in the company, valued at approximately $119,721.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shattuck Labs Stock Performance

Shares of STTK opened at $3.86 on Friday. The company’s fifty day simple moving average is $7.70 and its 200 day simple moving average is $8.36. Shattuck Labs, Inc. has a 1-year low of $1.33 and a 1-year high of $11.76.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.08. Shattuck Labs had a negative net margin of 3,133.63% and a negative return on equity of 64.85%. The company had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.30 million. The firm’s quarterly revenue was up 2200.0% compared to the same quarter last year. Equities analysts forecast that Shattuck Labs, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Trading of Shattuck Labs

Several institutional investors and hedge funds have recently bought and sold shares of the business. Cannon Global Investment Management LLC acquired a new position in shares of Shattuck Labs during the 1st quarter worth approximately $91,000. Tower Research Capital LLC TRC raised its position in shares of Shattuck Labs by 79.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock valued at $97,000 after purchasing an additional 5,989 shares during the period. Virtu Financial LLC acquired a new stake in shares of Shattuck Labs during the 1st quarter worth about $113,000. Reliant Investment Management LLC bought a new stake in shares of Shattuck Labs during the 4th quarter worth about $143,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Shattuck Labs during the 1st quarter worth about $174,000. Institutional investors own 58.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on STTK. Citigroup decreased their price objective on Shattuck Labs from $10.00 to $9.00 and set a “buy” rating for the company in a report on Monday, June 17th. BTIG Research cut shares of Shattuck Labs from a “buy” rating to a “neutral” rating in a report on Monday, June 17th. HC Wainwright lowered their price target on shares of Shattuck Labs from $28.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, June 20th. Finally, Needham & Company LLC reduced their price objective on shares of Shattuck Labs from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, June 14th.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.